Adjuvant therapy for colon cancer: genes, genes... and the patient in the center

Although molecular subtype-based stratification and genomic signatures of increasing complexity are becoming a new strategy to guide therapeutic decisions in stage II/III colon cancer, several prognostic factors that can be easily obtained from FFPE specimens should be considered in order to create combined models that better define individual patients needs

https://ift.tt/2HPPwPm